Researchers used a model that assumed an inadequate colon prep rate of 25 percent for the standard group and 5 percent for those who used the Pure-Vu. They used 2017 Medicare reimbursement data as a baseline.
Researchers then conducted a cost-minimization analysis considering the lifetime cost and incidence rate of a colonoscopy performed with the Pure-Vu system against a standard colonoscopy.
For high-risk patients, the Pure-Vu System:
- Reduced colorectal cancer incidence rate by 36 percent
- Minimized overall patient costs by up to $3,400 for private payers and up to $1,600 for Medicare beneficiaries
- Reduced the costs of repeated procedures attributable to inadequate prep by $804 for private payers and $951 for Medicare beneficiaries
The research was presented at Digestive Disease Week, June 2 to June 5 in Washington, D.C.
More articles on gastroenterology:
How to keep new patients coming in: 5 physician referral strategies for ASCs
ASC coding tip of the day: Collect every last penny
Medical device makers ‘shocked and disappointed’ by Trump’s proposed $50B tariffs — 5 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
